Tau Protein Phosphorylation Screening via Casein Kinase 1 Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively identify and target the enzymes responsible for phosphorylating paired helical filament tau and the specific sites phosphorylated by these enzymes, which is crucial for understanding and treating tauopathies such as Alzheimer's disease.
Innovation Solution
The identification of new phosphorylation sites in tau protein and the kinases responsible for these modifications, particularly casein kinase 1 (CK1) and src family kinases, provides a basis for developing therapeutic targets and screening methods to modulate tau protein phosphorylation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current screening methods are used to identify kinases responsible for tau phosphorylation, then the screening process can be conducted with existing tools, but the ability to effectively identify and target the specific enzymes and sites is insufficient
Solution Approach 1:
The patent segments the tau protein into specific regions containing predicted phosphorylation sites, allowing focused screening against individual site peptides rather than the entire tau protein. This segmentation enables precise identification of which specific kinases phosphorylate which specific sites, thereby improving both measurement precision and therapeutic targeting reliability
Solution Approach 2:
The patent applies local quality by creating synthetic peptides representing specific local regions of tau protein with predicted phosphorylation sites. Each peptide region is designed with specific properties (amino acid sequence, predicted site) to attract or inhibit specific kinases, enabling precise local targeting rather than global inhibition
2Adaptability or versatility
If new phosphorylation sites in PHF tau are identified to improve therapeutic targeting, then the specificity of treatment increases, but the complexity of the screening method increases
Solution Approach 1:
The patent performs preliminary action by using computational methods to predict phosphorylation sites in PHF tau before conducting the actual screening experiment. This pre-identification of target sites allows the screening to focus only on relevant regions, reducing the complexity of the experimental setup while maintaining high therapeutic specificity
Solution Approach 2:
The patent creates simplified copies of the tau protein's phosphorylation sites using synthetic peptides. These peptide copies contain the essential features (amino acid sequences and predicted phosphorylation sites) without the full complexity of the native tau protein structure, making screening more manageable while preserving therapeutic relevance
3Productivity
If computational methods are used to predict phosphorylation sites to reduce experimental workload, then the screening efficiency improves, but the accuracy of site identification may be compromised
Solution Approach 1:
The patent merges computational prediction methods with experimental validation in a hybrid screening approach. Computational methods are used to predict potential phosphorylation sites and generate candidate peptides, which are then tested experimentally to confirm actual kinase activity. This combination maintains high screening efficiency while ensuring identification accuracy through mutual validation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the development of assays and therapeutic strategies to inhibit or promote the phosphorylation of tau protein, potentially leading to treatments for tauopathies by targeting specific kinases and sites, thereby addressing the hyperphosphorylation associated with these diseases.
Implementation Method 1
screening for substances capable of modulating the phosphorylation of tau protein... identification of new phosphorylation sites in PHF tau and new kinases
Data Source
AI summary
Methods for screening for substances capable of modulating the phosphorylation of tau protein are disclosed, and in particular paired helical filament (PHF) tau, and the use of such modulators in the treatment of tauopathies. The assays and screening methods are based on the identification of new phosphorylation sites in PHF tau and new kinases and combinations of kinases as therapeutic targets, in particular the identification of casein kinase 1 as a kinase which phosphorylates tau protein.